In the case of Daraprim? Nowhere. It's not a drug many people need. Shrkreli himself has talked about this. It simply wouldn't be able to make a dent because of this, and it didn't.

If I'm recalling correctly, and I might not be, Shkreli is agnostic about the larger policy issue at hand, he simply made a choice for his own business that had little to no negative real impact.